Your browser doesn't support javascript.
loading
Associations of systemic health and medication use with the enlargement rate of geographic atrophy in age-related macular degeneration.
Shen, Liangbo L; Xie, Yangyiran; Sun, Mengyuan; Ahluwalia, Aneesha; Park, Michael M; Young, Benjamin K; Del Priore, Lucian V.
Afiliação
  • Shen LL; Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA.
  • Xie Y; Department of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Sun M; Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA.
  • Ahluwalia A; Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA.
  • Park MM; Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, New York, USA.
  • Young BK; Department of Ophthalmology and Visual Science, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Del Priore LV; Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut, USA lucian.delpriore@yale.edu.
Br J Ophthalmol ; 107(2): 261-266, 2023 Feb.
Article em En | MEDLINE | ID: mdl-34489337
BACKGROUND: The associations of geographic atrophy (GA) progression with systemic health status and medication use are unclear. METHODS: We manually delineated GA in 318 eyes in the Age-Related Eye Disease Study. We calculated GA perimeter-adjusted growth rate as the ratio between GA area growth rate and mean GA perimeter between the first and last visit for each eye (mean follow-up=5.3 years). Patients' history of systemic health and medications was collected through questionnaires administered at study enrolment. We evaluated the associations between GA perimeter-adjusted growth rate and 27 systemic health factors using univariable and multivariable linear mixed-effects regression models. RESULTS: In the univariable model, GA perimeter-adjusted growth rate was associated with GA in the fellow eye at any visit (p=0.002), hypertension history (p=0.03), cholesterol-lowering medication use (p<0.001), beta-blocker use (p=0.02), diuretic use (p<0.001) and thyroid hormone use (p=0.03). Among the six factors, GA in the fellow eye at any visit (p=0.008), cholesterol-lowering medication use (p=0.002), and diuretic use (p<0.001) were independently associated with higher GA perimeter-adjusted growth rate in the multivariable model. GA perimeter-adjusted growth rate was 51.1% higher in patients with versus without cholesterol-lowering medication use history and was 37.8% higher in patients with versus without diuretic use history. CONCLUSIONS: GA growth rate may be associated with the fellow eye status, cholesterol-lowering medication use, and diuretic use. These possible associations do not infer causal relationships, and future prospective studies are required to investigate the relationships further.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atrofia Geográfica / Degeneração Macular Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atrofia Geográfica / Degeneração Macular Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article